RWM
SUPN icon

Rialto Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Rialto Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Hold
3
– – ﹤0.01% 1874
2026
Q1 		$156 Sell
3
-1
-25% -$51 ﹤0.01% 1630
2025
Q4 		$199 Buy
4
+3
+300% +$146 ﹤0.01% 1529
2025
Q3 		$48 Hold
1
– – ﹤0.01% 1683
2025
Q2 		$32 Buy
+1
New +$32 ﹤0.01% 1668

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Rialto Wealth Management's SUPN Position: Q2 2026 in Review

Rialto Wealth Management held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 3 shares worth $140. The position accounts for ﹤0.01% of the portfolio, ranked #1874.

Rialto Wealth Management first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. The position peaked at $199 in Q4 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Rialto Wealth Management held 3 shares of Supernus Pharmaceuticals worth $140 as of Q2 2026.
  • Rialto Wealth Management left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1874 holding.
  • Rialto Wealth Management first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Rialto Wealth Management's Supernus Pharmaceuticals position peaked at $199 in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.